Compare AMPG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | ALXO |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 68.3M |
| IPO Year | N/A | 2020 |
| Metric | AMPG | ALXO |
|---|---|---|
| Price | $4.02 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | ★ 655.8K | 215.6K |
| Earning Date | 11-14-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,571,945.00 | N/A |
| Revenue This Year | $168.18 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.47 | N/A |
| 52 Week Low | $1.21 | $0.40 |
| 52 Week High | $4.89 | $2.27 |
| Indicator | AMPG | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 57.44 |
| Support Level | $3.36 | $1.07 |
| Resistance Level | $3.90 | $1.56 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 85.22 | 84.69 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.